Cardiovalve

Company Overview

Snapshot

Founded in January 2010 by Amir Gross, Cardiovalve operates with 51–200 employees. The company raised $45.48 million across two funding rounds from six investors. In March 2022, Cardiovalve was acquired by Venus Medtech.

Business overview

Cardiovalve develops cardiovascular replacement devices for minimally invasive surgery, focusing on solutions for mitral and tricuspid valve conditions. Its flagship system is designed for transfemoral/transseptal delivery, aiming to provide a less invasive alternative to open-heart surgery for mitral regurgitation. The company's technology minimizes protrusion into the left ventricle, enhancing safety and recovery for patients. Cardiovalve operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices industry with a focus on Medical Treatment & Therapeutics.

Strategic signal

In February 2020, Cardiovalve received 'Breakthrough Device Designation' from the FDA for its Transcatheter Tricuspid Valve Replacement System. This designation accelerates the development and review process for medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases, signaling strong regulatory validation and potential for rapid market entry for its innovative tricuspid valve technology.

Company Intelligence Q&A

What is Cardiovalve's primary focus?

Cardiovalve specializes in developing cardiovascular replacement devices designed for minimally invasive surgical procedures, particularly for mitral and tricuspid valve conditions.

When was Cardiovalve acquired?

Cardiovalve was acquired by Venus Medtech in March 2022.

Which investors participated in Cardiovalve's August 2020 funding round?

In August 2020, Cardiovalve received funding from investors including Edwards Lifesciences.

What significant regulatory milestone did Cardiovalve achieve?

In February 2020, Cardiovalve received 'Breakthrough Device Designation' from the FDA for its Transcatheter Tricuspid Valve Replacement System, acknowledging its potential to offer a more effective treatment for tricuspid regurgitation.

What is the core technology behind Cardiovalve's solutions?

Cardiovalve's core technology involves a transfemoral system designed to replace heart valves, offering a short profile for minimal protrusion into the left ventricle and aiming for easier procedures and quicker patient recovery compared to open-heart surgery.